Latest Breaking News On - Pharmaceuticals gmbh - Page 1 : comparemela.com

In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.

Claudia ulbrichNovo nordiskCardior pharmaceuticals gmbPharmaceuticals gmbhNovo nordiska sCardior pharmaceuticals gmbhCdr 132lHeart diseaseMir 132Deals andm amp aMir 132 inhibitorNoncoding rnaHeart failureCardiac hypertrophy